{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:35:43Z","timestamp":1792521343215,"version":"4.5.0"},"reference-count":51,"publisher":"International Association of Physical Chemists (IAPC)","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ADMET DMPK"],"abstract":"<jats:p>Background and purpose: Tuberculosis (TB), a serious global health concern, continues to contribute to the global health burden, underscoring the urgent need to discover potent antitubercular agents. In the present study, a series of novel 5,6-diphenyl-1,2,4-triazine-piperazine derivatives were synthesized, and their potential for anti-tubercular activity was assessed. Experimental approach: The antitubercular potential of the synthesized compounds was assessed using the microplate alamar blue assay (MABA). Cytotoxicity studies were carried out on RAW 264.7 macrophages. To assess the mode of action of the synthesized compounds, docking analysis of the active compounds was performed on two key enzymes of Mycobacterium, decaprenylphosphoryl-\u03b2-D-ribose 2\u2032-epimerase and Mycobacterium tuberculosis-dihydro\u00adfolate reductase (Mtb-DHFR). Furthermore, molecular dynamics simulations and density functional theory calculations were performed to validate the stability of the ligand\u2013protein complexes and the electronic properties of the lead compounds. Key results: The results revealed promising anti-tubercular activity for the synthesized compounds. Among these, compounds 2-((5,6-Diphenyl-1,2,4-triazin-3-yl)thio)--1-(4-(4-fluoro\u00adbenzoyl)pi\u00adperazin-1-yl)ethan-1-one (FP3) and 2-((5,6-diphenyl-1,2,4-triazin-3-yl)thio)-1-(4-(4-methylbe\u00adnzoyl) piperazin-1-yl)ethan-1-one (FP8) exhibited potent activity with an minimum inhibitory concentration of 1.6\u00a0\u00b5g\u00a0mL\u207b\u00b9, along with promising cytotoxicity profiles against RAW 264.7 macrophage cells. Docking studies revealed potent docking scores compared to the standard, thereby confirming the involvement of the DHFR enzyme. Interaction analysis revealed stable hydrogen-bond interactions, \u03c0-\u03c0 stacking, and hydrophobic interactions with the active-site residues of the DHFR enzyme. Additionally, molecular dynamics simulation validated the stability of the interactions and the structural integrity of the complexes, while density functional theory calculations supported the desirable electronic properties of the lead compounds. Conclusion: The combined results of the experiments and calculations validated the potential of FP3 and FP8 as DHFR-targeted antitubercular agents. The study highlights the potential of 5,6-diphenyl-1,2,4-triazine-piperazine derivatives as promising candidates for further anti-tubercular drug development.<\/jats:p>","DOI":"10.5599\/admet.3322","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T03:00:12Z","timestamp":1780887612000},"source":"Crossref","is-referenced-by-count":2,"title":["Design, synthesis and antitubercular evaluation of novel 5,6-diphenyl-1,2,4-triazine-piperazine derivatives targeting mycobacterial dihydrofolate reductase"],"prefix":"10.5599","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5646-1198","authenticated-orcid":false,"family":"Uday Thakkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2586-1869","authenticated-orcid":false,"given":"Moksh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4511-8875","authenticated-orcid":false,"family":"Pratik Khona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0474-2509","authenticated-orcid":false,"family":"Harnisha Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2020-5225","authenticated-orcid":false,"family":"Mange Ram Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9687-3479","authenticated-orcid":false,"family":"Salman Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6248-5013","authenticated-orcid":false,"family":"Chanchal Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1510-8993","authenticated-orcid":false,"family":"Renuka Bhamre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9016-1507","authenticated-orcid":false,"family":"Afzal Nagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3564","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"183409","doi-asserted-by":"crossref","unstructured":"[1] S. Bagcchi. WHO\u2019s Global Tuberculosis Report 2022. The Lancet Microbe 4 (2023) e20. https:\/\/doi.org\/10.1016\/S2666-5247(22)00359-7","DOI":"10.1016\/S2666-5247(22)00359-7"},{"key":"183410","doi-asserted-by":"crossref","unstructured":"[2] N. Chirra, N.P. Abburi, E.M. Rekha, et al. N-Substituted piperazine-coupled imidazo[2,1-b]thiazoles as inhibitors of Mycobacterium tuberculosis: Synthesis, evaluation, and docking studies. Drug Development Research 85 (2024) 1. https:\/\/doi.org\/10.1002\/ddr.22153","DOI":"10.1002\/ddr.22153"},{"key":"183411","doi-asserted-by":"crossref","unstructured":"[3] S. Dash, E. Rathi, A. Kumar, K. Chawla, A. Joseph, S.G. Kini. Structure-activity relationship mediated molecular insights of DprE1 inhibitors: A comprehensive review. Journal of Biomolecular Structure and Dynamics 42 (2024) 6472-6522. https:\/\/doi.org\/10.1080\/07391102.2023.2230312","DOI":"10.1080\/07391102.2023.2230312"},{"key":"183412","doi-asserted-by":"crossref","unstructured":"[4] M.S.I.T. Makki, R.M. Abdel-Rahman, H.M. Faidallah, K.A. Khan. Synthesis of new fluorine substituted heterocyclic nitrogen systems derived from p-aminosalicylic acid as antimycobacterial agents. Journal of Chemistry 2013 (2013) 819462. https:\/\/doi.org\/10.1155\/2013\/819462","DOI":"10.1155\/2013\/819462"},{"key":"183413","doi-asserted-by":"crossref","unstructured":"[5] M. Borham, A. Oreiby, A. El-Gedawy, et al. Review on bovine tuberculosis: An emerging disease associated with multidrug-resistant Mycobacterium species. Pathogens 11 (2022) 715. https:\/\/doi.org\/10.3390\/pathogens11070715","DOI":"10.3390\/pathogens11070715"},{"key":"183414","doi-asserted-by":"crossref","unstructured":"[6] M. Shah, I. Patel, P. Khona, H. Patel, M.R. Yadav, A. Nagani. Pyrazolopyridine pyrimidone hybrids as potential DprE1 inhibitors: Design, synthesis and biological evaluation as antitubercular agents. Scientific Reports 15 (2025) 29586. https:\/\/doi.org\/10.1038\/s41598-025-14734-1","DOI":"10.1038\/s41598-025-14734-1"},{"key":"183415","doi-asserted-by":"crossref","unstructured":"[7] V. Singh. Tuberculosis treatment-shortening. Drug Discovery Today 29 (2024) 103955. https:\/\/doi.org\/10.1016\/j.drudis.2024.103955","DOI":"10.1016\/j.drudis.2024.103955"},{"key":"183416","doi-asserted-by":"crossref","unstructured":"[8] J.G. Jang, J.H. Chung. Diagnosis and treatment of multidrug-resistant tuberculosis. Yeungnam University Journal of Medicine 37 (2020) 277-285. https:\/\/doi.org\/10.12701\/yujm.2020.00626","DOI":"10.12701\/yujm.2020.00626"},{"key":"183417","doi-asserted-by":"crossref","unstructured":"[9] V.A. Dartois, E.J. Rubin. Anti-tuberculosis treatment strategies and drug development: Challenges and priorities. Nature Reviews Microbiology 20 (2022) 685-701. https:\/\/doi.org\/10.1038\/s41579-022-00731-y","DOI":"10.1038\/s41579-022-00731-y"},{"key":"183418","doi-asserted-by":"crossref","unstructured":"[10] R. Sehrawat, P. Rathee, S. Khatkar, et al. Dihydrofolate reductase (DHFR) inhibitors: A comprehensive review. Current Medicinal Chemistry 31 (2024) 799-824. https:\/\/doi.org\/10.2174\/0929867330666230310091510","DOI":"10.2174\/0929867330666230310091510"},{"key":"183419","doi-asserted-by":"crossref","unstructured":"[11] N.G. Sonawane, A. Thakur, A.K.S. Pillai, A. Sharma, A.P. Gunjal, K. Sharma. Recent cutting-edge designing strategies for Mtb-DHFR inhibitors as antitubercular agents. Chemical Biology & Drug Design 104 (2024) 6. https:\/\/doi.org\/10.1111\/cbdd.70027","DOI":"10.1111\/cbdd.70027"},{"key":"183420","doi-asserted-by":"crossref","unstructured":"[12] Y.S. Cheng, J.C. Sacchettini. Structural insights into Mycobacterium tuberculosis Rv2671 protein as a dihydrofolate reductase functional analogue contributing to para-aminosalicylic acid resistance. Biochemistry 55 (2016) 1107-1119. https:\/\/doi.org\/10.1021\/acs.biochem.5b00993","DOI":"10.1021\/acs.biochem.5b00993"},{"key":"183421","doi-asserted-by":"crossref","unstructured":"[13] N. Salih, J. Salimon, H. Hussien. Synthesis, characterization and in vitro antibacterial activity of novel 1,2,4-triazine and 1,2-diazepine derivatives. Biointerface Research in Applied Chemistry 12 (2022) 3055-3065. https:\/\/doi.org\/10.33263\/BRIAC123.30553065","DOI":"10.33263\/BRIAC123.30553065"},{"key":"183422","doi-asserted-by":"crossref","unstructured":"[14] R.V. Patel, P. Kumari, D.P. Rajani, C. Pannecouque, E. De Clercq, K.H. Chikhalia. Antimicrobial, anti-TB, anticancer and anti-HIV evaluation of new s-triazine-based heterocycles. Future Medicinal Chemistry 4 (2012) 1053-1065. https:\/\/doi.org\/10.4155\/fmc.12.57","DOI":"10.4155\/fmc.12.57"},{"key":"183423","doi-asserted-by":"crossref","unstructured":"[15] A.A.M. El-Reedy, N.K. Soliman. Synthesis, biological activity and molecular modeling study of novel 1,2,4-triazolo[4,3-b][1,2,4,5]tetrazines and 1,2,4-triazolo[4,3-b][1,2,4]triazines. Scientific Reports 10 (2020) 6137. https:\/\/doi.org\/10.1038\/s41598-020-62977-x","DOI":"10.1038\/s41598-020-62977-x"},{"key":"183424","doi-asserted-by":"crossref","unstructured":"[16] D. Cai, T. Li, Q. Xie, et al. Synthesis, characterization, and biological evaluation of novel 7-oxo-7H-thiazolo[3,2-b]-1,2,4-triazine-2-carboxylic acid derivatives. Molecules 25 (2020) 1307. https:\/\/doi.org\/10.3390\/molecules25061307","DOI":"10.3390\/molecules25061307"},{"key":"183425","doi-asserted-by":"crossref","unstructured":"[17] E.V. Shchegol\u2019kov, O.G. Khudina, A.E. Ivanova, et al. Synthesis and tuberculostatic activity of some 1,2,4-triazines. Pharmaceutical Chemistry Journal 48 (2014) 383-386. https:\/\/doi.org\/10.1007\/s11094-014-1115-6","DOI":"10.1007\/s11094-014-1115-6"},{"key":"183426","doi-asserted-by":"crossref","unstructured":"[18] A. Jaggal, K.S. Katagi, M. Akki, V. Babagond, V. Kamat, S. Joshi. A click-chemistry based strategy for synthesizing coumarin piperazine analogues: Assessment of anti-tubercular, anti-cancer, anti-inflammatory and antioxidant potentials. Journal of Molecular Structure 1320 (2025) 139388. https:\/\/doi.org\/10.1016\/j.molstruc.2024.139388","DOI":"10.1016\/j.molstruc.2024.139388"},{"key":"183427","doi-asserted-by":"crossref","unstructured":"[19] K. Patel, A. Nagani, M. Shah, K. Patel. Design, synthesis, and biological evaluation of natural carbolic acid-pyrazinamide hybrids as antimicrobial agents. ChemistrySelect 10 (2025) e202503152. https:\/\/doi.org\/10.1002\/slct.202503152","DOI":"10.1002\/slct.202503152"},{"key":"183428","doi-asserted-by":"crossref","unstructured":"[20] K. Patel, M. Shah, K. Patel, A. Nagani. Recent advances in piperazine derivatives as antibacterial agents: A comprehensive review (2020-2024). Molecular Diversity (2025). https:\/\/doi.org\/10.1007\/s11030-025-11311-6","DOI":"10.1007\/s11030-025-11311-6"},{"key":"183429","doi-asserted-by":"crossref","unstructured":"[21] S. Buloyan, A. Harutyunyan, H. Gasparyan, et al. Piperazine-substituted pyranopyridines exhibit antiproliferative activity and act as inhibitors of HBV virion production. International Journal of Molecular Sciences 26 (2025) 3991. https:\/\/doi.org\/10.3390\/ijms26093991","DOI":"10.3390\/ijms26093991"},{"key":"183430","doi-asserted-by":"crossref","unstructured":"[22] Y. Liu, H. Xin, Y. Wang, et al. Flavonol derivatives containing piperazine and quinoxaline fragments: Synthesis and antifungal activity. Molecular Diversity 29 (2025) 2193-2208. https:\/\/doi.org\/10.1007\/s11030-024-10977-8","DOI":"10.1007\/s11030-024-10977-8"},{"key":"183431","doi-asserted-by":"crossref","unstructured":"[23] D. Parmar, R.K.P. Tripathi, R. Panchal, A. Nagani, U.D. Kabra. New quinazolinone-thiouracil derivatives: Design, synthesis, anticancer evaluation, and in silico analysis. ChemistrySelect 9 (2024) e202403717. https:\/\/doi.org\/10.1002\/slct.202403717","DOI":"10.1002\/slct.202403717"},{"key":"183432","doi-asserted-by":"crossref","unstructured":"[24] M. Almehmadi, M. Allahyani, A.A. Alsaiari, M. Asif, S. Kumar. Neuropharmacological potential of different piperazine analogs: A recent prospective. Mini-Reviews in Organic Chemistry 22 (2025) 65-84. https:\/\/doi.org\/10.2174\/0118756298277743231213065544","DOI":"10.2174\/0118756298277743231213065544"},{"key":"183433","doi-asserted-by":"crossref","unstructured":"[25] A. Nagani, M. Shah, S. Patel, et al. Unveiling piperazine-quinoline hybrids as potential multi-target directed anti-Alzheimer\u2019s agents: Design, synthesis and biological evaluation. Molecular Diversity 29 (2025) 1453-1478. https:\/\/doi.org\/10.1007\/s11030-024-10927-4","DOI":"10.1007\/s11030-024-10927-4"},{"key":"183434","doi-asserted-by":"crossref","unstructured":"[26] S. Tripathi, R. Kumar, A. Debnath, H. Singh, R.K. Yadav, Salahuddin. Design, synthesis, docking, DFT, and MD simulation studies of new piperazine, 1,3,4-oxadiazole, and quinoline conjugates: A search for potent antiepileptic agents. Bioorganic Chemistry 162 (2025) 108595. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108595","DOI":"10.1016\/j.bioorg.2025.108595"},{"key":"183435","doi-asserted-by":"crossref","unstructured":"[27] J. Piton, A. Vocat, A. Lupien, et al. Structure-based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 62 (2018) e00681-18. https:\/\/doi.org\/10.1128\/AAC.00681-18","DOI":"10.1128\/AAC.00681-18"},{"key":"183436","doi-asserted-by":"crossref","unstructured":"[28] M. Imran, A.S. A., H.K. Thabet, Abida, M.A. Bakht. Synthetic molecules as DprE1 inhibitors: A patent review. Expert Opinion on Therapeutic Patents 31 (2021) 759-772. https:\/\/doi.org\/10.1080\/13543776.2021.1902990","DOI":"10.1080\/13543776.2021.1902990"},{"key":"183437","doi-asserted-by":"crossref","unstructured":"[29] L. Liu, C. Kong, M. Fumagalli, et al. Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents. European Journal of Medicinal Chemistry 208 (2020) 112773. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112773","DOI":"10.1016\/j.ejmech.2020.112773"},{"key":"183438","doi-asserted-by":"crossref","unstructured":"[30] J. Shaikh, S. Patel, A. Nagani, et al. Pharmacophore mapping, 3D QSAR, molecular docking, and ADME prediction studies of novel benzothiazinone derivatives. Silico Pharmacology 12 (2024) 79. https:\/\/doi.org\/10.1007\/s40203-024-00255-8","DOI":"10.1007\/s40203-024-00255-8"},{"key":"183439","doi-asserted-by":"crossref","unstructured":"[31] H. Patel, A. Nagani, M. Patel, M. Patel, M.R. Yadav. Design, synthesis and biological evaluation of some imidazo[1,2-a]pyridine derivatives as anti-tubercular agents: An in silico-in vitro approach. Journal of Biomolecular Structure and Dynamics (2024) 1-18. https:\/\/doi.org\/10.1080\/07391102.2024.2436554","DOI":"10.1080\/07391102.2024.2436554"},{"key":"183440","doi-asserted-by":"crossref","unstructured":"[32] P. Patel, M. Shah, P. Khona, et al. Piperazinyl-N-aryl acetamides and 1,3,4-thiadiazole hybrids as potential DprE1 inhibitors: Design, synthesis and biological evaluation as antitubercular agents. Journal of Molecular Structure 1346 (2025) 143167. https:\/\/doi.org\/10.1016\/j.molstruc.2025.143167","DOI":"10.1016\/j.molstruc.2025.143167"},{"key":"183441","doi-asserted-by":"crossref","unstructured":"[33] S.R. Shinde, S.N. Inamdar, V.A. Obakachi, et al. Discovery of oxazole-dehydrozingerone based hybrid molecules as potential anti-tubercular agents and their docking for Mtb DNA gyrase. Results in Chemistry 4 (2022) 100374. https:\/\/doi.org\/10.1016\/j.rechem.2022.100374","DOI":"10.1016\/j.rechem.2022.100374"},{"key":"183442","doi-asserted-by":"crossref","unstructured":"[34] A.C. Lele, A. Raju, M.P. Khambete, et al. Design and synthesis of a focused library of diamino triazines as potential Mycobacterium tuberculosis DHFR inhibitors. ACS Medicinal Chemistry Letters 6 (2015) 1140-1144. https:\/\/doi.org\/10.1021\/acsmedchemlett.5b00367","DOI":"10.1021\/acsmedchemlett.5b00367"},{"key":"183443","doi-asserted-by":"crossref","unstructured":"[35] S. Hou, T. Li, J. Yan, et al. Design, synthesis and antibacterial activity of novel 7H-thiazolo[3,2-b]-1,2,4-triazin-7-one derivatives. Heliyon 10 (2024) e24589. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24589","DOI":"10.1016\/j.heliyon.2024.e24589"},{"key":"183444","doi-asserted-by":"crossref","unstructured":"[36] V. Makarov, B. Lechartier, M. Zhang, et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Molecular Medicine 6 (2014) 372-383. https:\/\/doi.org\/10.1002\/emmm.201303575","DOI":"10.1002\/emmm.201303575"},{"key":"183445","doi-asserted-by":"crossref","unstructured":"[37] R. Li, R. Sirawaraporn, P. Chitnumsub, et al. Three-dimensional structure of Mycobacterium tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. Journal of Molecular Biology 295 (2000) 307-323. https:\/\/doi.org\/10.1006\/jmbi.1999.3328","DOI":"10.1006\/jmbi.1999.3328"},{"key":"183446","unstructured":"[38] BIOVIA, Dassault Syst\u00e8mes (2021). Discovery Studio Modeling Environment, Release 2021. San Diego: Dassault Syst\u00e8mes."},{"key":"183447","doi-asserted-by":"crossref","unstructured":"[39] K.J. Bowers, F.D. Sacerdoti, J.K. Salmon, Y. Shan, D.E. Shaw, E. Chow, H. Xu, R.O. Dror, M.P. Eastwood, et al. Molecular dynamics\u2014Scalable algorithms for molecular dynamics simulations on commodity clusters. Proceedings of the 2006 ACM\/IEEE Conference on Supercomputing (2006) 84. https:\/\/doi.org\/10.1145\/1188455.1188544.","DOI":"10.1145\/1188455.1188544"},{"key":"183448","doi-asserted-by":"crossref","unstructured":"[40] S. Sheoran, S. Arora, T. Basu, et al. In silico analysis of diosmetin as an effective chemopreventive agent against prostate cancer: Molecular docking, validation, dynamic simulation and pharmacokinetic prediction-based studies. Journal of Biomolecular Structure and Dynamics 42 (2024) 9105-9117. https:\/\/doi.org\/10.1080\/07391102.2023.2250451","DOI":"10.1080\/07391102.2023.2250451"},{"key":"183449","doi-asserted-by":"crossref","unstructured":"[41] A.D. Bochevarov, E. Harder, T.F. Hughes, et al. Jaguar: A high-performance quantum chemistry software program with strengths in life and materials sciences. International Journal of Quantum Chemistry 113 (2013) 2110-2142. https:\/\/doi.org\/10.1002\/qua.24481","DOI":"10.1002\/qua.24481"},{"key":"183450","doi-asserted-by":"crossref","unstructured":"[42] H. Kruse, L. Goerigk, S. Grimme. Why the standard B3LYP\/6-31G* model chemistry should not be used in DFT calculations of molecular thermochemistry: Understanding and correcting the problem. Journal of Organic Chemistry 77 (2012) 10824-10834. https:\/\/doi.org\/10.1021\/jo302156p","DOI":"10.1021\/jo302156p"},{"key":"183451","doi-asserted-by":"crossref","unstructured":"[43] V. Yele, D.K. Sigalapalli, S. Jupudi, A.A. Mohammed. DFT calculation, molecular docking, and molecular dynamics simulation study on substituted phenylacetamide and benzohydrazide derivatives. Journal of Molecular Modeling 27 (2021) 359. https:\/\/doi.org\/10.1007\/s00894-021-04987-8","DOI":"10.1007\/s00894-021-04987-8"},{"key":"183452","doi-asserted-by":"crossref","unstructured":"[44] S. Shamim, K.M. Khan, N. Ullah, et al. Synthesis and screening of (E)-3-(2-benzylidenehydrazinyl)-5,6-diphenyl-1,2,4-triazine analogs as novel dual inhibitors of \u03b1-amylase and \u03b1-glucosidase. Bioorganic Chemistry 101 (2020) 103979. https:\/\/doi.org\/10.1016\/j.bioorg.2020.103979","DOI":"10.1016\/j.bioorg.2020.103979"},{"key":"183453","doi-asserted-by":"crossref","unstructured":"[45] M. Yazdani, N. Edraki, R. Badri, M. Khoshneviszadeh, A. Iraji, O. Firuzi. Multi-target inhibitors against Alzheimer disease derived from 3-hydrazinyl 1,2,4-triazine scaffold containing pendant phenoxy methyl-1,2,3-triazole: Design, synthesis and biological evaluation. Bioorganic Chemistry 84 (2019) 363-371. https:\/\/doi.org\/10.1016\/j.bioorg.2018.11.03","DOI":"10.1016\/j.bioorg.2018.11.038"},{"key":"183454","doi-asserted-by":"crossref","unstructured":"[46] S. Cho, H.S. Lee, S. Franzblau. Microplate Alamar Blue Assay (MABA) and low oxygen recovery assay (LORA) for Mycobacterium tuberculosis. In: Methods in Molecular Biology, Springer, New York, USA, 2015, pp. 281-292. https:\/\/doi.org\/10.1007\/978-1-4939-2450-9_17","DOI":"10.1007\/978-1-4939-2450-9_17"},{"key":"183455","doi-asserted-by":"crossref","unstructured":"[47] D.M.L. Morgan. Tetrazolium (MTT) assay for cellular viability and activity. In: Polyamine Protocols, Humana Press, Totowa, NJ, USA, 2000, pp. 179-184. https:\/\/doi.org\/10.1385\/0-89603-448-8:179","DOI":"10.1385\/0-89603-448-8:179"},{"key":"183456","doi-asserted-by":"crossref","unstructured":"[48] J. van Meerloo, G.J.L. Kaspers, J. Cloos. Cell sensitivity assays: The MTT assay. In: Methods in Molecular Biology, Springer, New York, USA, 2011, pp. 237-245. https:\/\/doi.org\/10.1007\/978-1-61779-080-5_20","DOI":"10.1007\/978-1-61779-080-5_20"},{"key":"183457","doi-asserted-by":"crossref","unstructured":"[49] A. Daina, O. Michielin, V. Zoete. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports 7 (2017) 42717. https:\/\/doi.org\/10.1038\/srep42717","DOI":"10.1038\/srep42717"},{"key":"183458","doi-asserted-by":"crossref","unstructured":"[50] G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A.J. Olson, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry 30 (2009) 2785\u20132791. https:\/\/doi.org\/10.1002\/jcc.21256","DOI":"10.1002\/jcc.21256"},{"key":"183459","doi-asserted-by":"crossref","unstructured":"[51] J. He, C. Li, W. Hu, C. Li, S. Liu, J. Sui, T. Zhang, Q. Sun, Y. Luo, Identification of selective mtb DHFR inhibitors by virtual screening and experimental approaches, Chem. Biol. Drug Des. 100 (2022) 1005-1016. https:\/\/doi.org\/10.1111\/cbdd.14018.","DOI":"10.1111\/cbdd.14018"}],"container-title":["ADMET and DMPK"],"original-title":[],"link":[{"URL":"https:\/\/pub.iapchem.org\/ojs\/index.php\/admet\/article\/download\/3322\/2930","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pub.iapchem.org\/ojs\/index.php\/admet\/article\/download\/3322\/2930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T03:00:47Z","timestamp":1780887647000},"score":1,"resource":{"primary":{"URL":"https:\/\/pub.iapchem.org\/ojs\/index.php\/admet\/article\/view\/3322"}},"subtitle":["Original scientific article"],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":51,"URL":"https:\/\/doi.org\/10.5599\/admet.3322","relation":{},"ISSN":["1848-7718"],"issn-type":[{"value":"1848-7718","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"article-number":"3322"}}